Emerging therapies for MS

Revue Neurologique

Volumn 163, Issue 6-7, 2007, Pages 688-696

  Waubant, E ^a  

^a UCSF Multiple Sclerosis Center   (United States)

Author keywords

Emerging therapies; Multiple sclerosis; Phase I and II trials

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; LAQUINIMOD; RITUXIMAB;

ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE ACTIVATION; CONFERENCE PAPER; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34347366083     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(07)90481-6     Document Type: Conference Paper

References (62)

1. BAR-OR A, CALABRESI P, ARNOLD D, MARKOWITZ C, SHAFER S, KASPER L, WAUBANT E, GAZDA S, FOX R, SARKAR S, PANZARA M, SMITH C. (2007). A phase I open-label, multicenter study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis. Neurology (suppl1), 68: A84.
2. BEBO B F, A FYFE-JOHNSON, K ADLARD, AG BEAM, AA VANDENBARK, AND H OFFNER. (2001). Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol, 166: 2080.
3. BEN-NUN A, WEKERLE H, COHEN IR. (1981). Vaccination against autoimmune encephalomyelitis with T-lymphocytes cell lines reactive against myelin basic protein. Nature, 292: 60-61.
4. BIELEKOVA B, B GOODWIN, N RICHERT et al. (2000). Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med, 6: 1167.
5. BIELEKOVA B, RICHERT N, HOWARD T, BLEVINS G, MARKOVIC-PLESE S, MCC ARTIN J, FRANK JA, WURFEL J, OHAYON J, WALDMANN TA, MCFARLAND HF, MARTIN R. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci, 101: 8705-8708.
6. BOURDETTE DN, CHOU YK, WHITHAM RH et al. (1998). Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes. J Immunol, 161: 1034-1044.
7. BRUNDULA V, REWCASTLE NB, METZ LM, BERNARD CC, YONG VW. (2002). Targeting leukocyte MMPs and transmigration. Minocyclin as a potential therapy for multiple sclerosis. Brain, 125: 1297-1308.
8. CAO L, SUN D, CRUZ T, MOSCARELLO MA, LUDWIN SK, WHITAKER JN. (2000). Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel. J Neuroimmunol, 108: 103-111.
9. COLES A. (2007) the CAMMS223 Study group. Efficacy of alemtuzumab in treatment-naïve relapsing-remitting multiple sclerosis: analysis after two years of study CAMMS223. Neurology (suppl1), 68: A100.
10. COMI G, ABRAMSKI O, ARBISU T, BOIKO A, GOLD R, HAVRDOVA E, KOMOLY S, SELMAJ K, SHARRACK B, FILIPPI M for the LAQ/5062 Study group. (2007). The effect of two doses of laquinomod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, placebo-controlled study. Neurology (suppl1), 68: A84.
11. CORREALE J, LUND B, MCMILLAN M, KO DY, MCCARTHY K, WEINER LP. (2000). T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol, 107: 130-139.
12. CREE B, LAMB S, MORGAN K et al. (2005). An open label study of the effects of rituximab in neuromyelitis optica. Neurology, 64: 1270-1272.
13. CROSS AH, GIRARD TJ, GIACOLETTO KS et al. (1995). Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest, 95: 2783-2789.
14. CROSS AH, STARK JL, LAUBER J, RAMSBOTTOM MJ, LYONS J. (2006). Rituximab reduces B cells and T cells in the cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol, 180: 63-70.
15. FASSAS A, PASSWEG JR, ANAGNOSTOPOULOS A et al. (2002). Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol, 249: 1088-1097.
16. GUO X, DILLMAN JF 3RD, DAWSON VL, DAWSON TM. (2001). Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. Ann Neurol, 50: 6-16.
17. GILGUN-SHERKI Y, PANET H, MELAMED E, OFFEN D. (2003). Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Research, 989: 196-204.
18. HAUSER SL, WAUBANT E, ARNOLD D, VOLLMER T, ANTEL J, FOX R, BAR-OR A, SARKAR N, LANGER-GOULD A, PANZARA M, SMITH C. (2007). A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing-remitting MS. Neurology (suppl1), 68: A99.
19. HOHLFELD R. (1997). Biotechnical agents for the immunotherapy of MS: Principles, problems and perspectives. Brain, 120: 865-916.
20. HURD R, SAILASUTA N, SRINIVASAN R, VIGNERON D, PELLETIER D, NELSON SJ. (2004). Measurement of Brain Glutamate using TE-averaged PRESS at 3T. Mag Reson Med, 51: 435-440.
21. JACOBSOHN DA. (2002). Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs, 11: 1271-1280.
22. JANSSON L, OLSSON T, HOLMDAHL R. (1994). Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J Neuroimmunol, 53: 203.
23. KALKERS NF, BARKHOF F, BERGERS E, VAN SCHIJNDEL R, POLMAN CH. (2002). The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler, 8: 532-533.
24. KAPPOS L, G COMI, H PANITCH et al. (2000). Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med, 6: 1176.
25. KAPPOS L, ANTEL J, COMI G, MONTALBAN X, O'CONNOR P, POLMAN CH, HAAS T, KORN AA, KARLSSON G, RADUE EW; FTY720 D2201 Study Group. (2006). Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J MedSep, 355: 1124-1140.
26. KHOURY SJ, AKALIN E, CHANDRAKER A et al. (1995). CD28-B7 costimulatory blockade by CTLA-4 Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol, 155: 4521-4524.
27. KHOURY SJ. (2004). Safety of CTLA4-Ig in relapsing-remitting MS. Neurology (suppl).
28. KILLESTEIN SJ, KALKERS NF, POLMAN CH. (2005). Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci, 233: 113-115.
29. KOTZIN BL, KARUTURI S, CHOU YK et al. (1991). Preferential T cell receptor ß-chain variable gene use in myelin basic protein-reactive T cell clones from patients with multiple sclerosis. Proc Natl Acad Sci, 88: 9161-9165.
30. KWAK B, MULHAUPT F, MYIT S, MACH F. (2000). Statins as a newly recognized type of immunomodulator. Nat Med, 6: 1399-1402.
31. MANDALFINO P, RICE G, SMITH A, KLEIN JL, RYSTEDT L, EBERS GC. (2000). Bone marrow transplantation in multiple sclerosis. J Neurol, 247: 691-695.
32. MARRACCI GH, JONES RE, MCKEON GP, BOURDETTE DN. (2002). Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol, 131: 104-114.
33. MEDAER R, STINISSEN P, TRUYEN L, RAUS J, ZHANG J. (1995). Depletion of myelin-basic-protein-autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet, 346: 807-808.
34. METZ LM, ZHANG Y, YEUNG M, PATRY DG, BELL RB, STOIAN CA, YONG VW, PATTEN SB, DUQUETTE P, ANTEL JP, MITCHELL JR. (2004). Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol. May, 55: 756.
35. MONSON N, CRAVENS P, FROHMAN E et al. (2005). Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol, 62: 258-264.
36. MOREAU T, THORPE J, MILLER D et al. (1994). Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet, 344: 298-301.
37. MOREAU T, COLES A, WING M et al. (1996). Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain, 119: 225-237.
38. MORGAN EE, NARDO CJ, DIVELEY JP et al. (2001). Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. J Neurosci Res, 64: 298-301.
39. O'CONNOR PW, LI D, FREEDMAN MS, BAR-OR A, RICE GP, CONFAVREUX C, PATY DW, STEWART JA, SCHEYER R. (2006). Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology, 66: 894-900.
40. OLEK MJ, SMITH DJ, COOK SL, KHOURY SJ, WEINER HL. (2001). Phase 1 study of oral recombinant ovine interferon-tau in relapsing-remitting multiple sclerosis. Neurology (Suppl 3), 56: A76.
41. PAHAN K, SHEIKH FG, NAMBOODIRI AM, SINGH I. (1997). Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest, 100: 2671-2679.
42. PELUFFO H, ESTEVEZ A, BARBEITO L, STUTZMAN JM. (1997). Riluzole promotes survival of rat motoneurons in vitro by stimulating trophic activity produced by spinal astrocyte monolayers. Neuroscience Letter, 228: 207-211.
43. PITT D, WERNER P, RAINE C. (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nature Med, 6: 67-70.
44. PITT D, NAGELMEIER IE, WILSON HC, RAINE CS. (2003). Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology, 61: 1113-1120.
45. POPOVIC N, SCHUBART A, GOETZ BD, ZHANG SC, LININGTON C, DUNCAN ID. (2002) Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol, 51(2): 215-223.
46. ROTTMAN JB, AJ SLAVIN, R SILVA, HL WEINER, CG GERARD, WW HANCOCK. (2000). Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol, 8: 2372-2377.
47. ROSE JW, WATT HE, WHITE AT, CARLSON NG. (2004). Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol, 56: 864-867.
48. SCHIMRIGK S, BRUNE N, HELLWIG K, LUKAS C, BELLENBERG B, RIEKS M, HOFFMANN V, POHLAU D, PRZUNTEK H. (2006). Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol, 13: 604-610.
49. SICOTTE N, P PFIEFFER, R KLUTCH et al. (2002). Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol, 52: 421-428.
50. SMITH T, GROOM A, ZHU B, TURSKI L. (2000). Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nature Medicine 6: 62-66.
51. SOOS JM, SUBRAMIAN PS, HOBEIKA AC, SCHIFFENBAUER J, JOHNSON HM. (1995). The interferon pregnancy recognition hormone, interferon tau, blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol, 155: 2747-2753.
52. SOOS JM, MUSTAFA GM, SUBRAMANIAN PS, STREIT WJ, JOHNSON HJ. (1997). Oral feeding of intereron τ can prevent acute and chronic relapsing forms of experimental allergic encephalomyelitis. J Neurimmunol, 75: 43-50.
53. STUVE O, CEPOK S, ELIAS B et al. (2005). Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol, 62: 1620-1623.
54. TREBST C, SORENSEN TL, KIVISAKK et al. (2001). CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol, 159: 1701-1710.
55. VANDENBARK AA, CHOU YK, WITHAM R et al. (1996). Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nature Medicine, 2: 1109-1115.
56. VOLLMER T, KEY L, DURKALSKI V, TYOR W, CORBOY J, MARKOVIC-PLESE S, PREININGEROVA J, RIZZO M, SINGH I. (2004). Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet, 363: 1607-1608.
57. WAUBANT E, BUCKLE G, BOURDETTE D, KACHUCK N, GILMAN D, VILLARETE L, LIU CP, SHARMA J, EGOROVA S, BAKSHI R, GUTTMAN C, WEINER H. (2005). A phase II study of oral ovine interferon tau in clinically isolated syndromes (CIS) or relapsing remitting (RR) MS. Multiple Sclerosis.
58. WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al. (2001). Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med, 7: 687-692.
59. WERNER P, PITT D, RAINE C. (2001). Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol, 50: 169-180.
60. YOUSSEF S, STUVE O, PATARROYO JC et al. (2002). The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in CNS autoimmune disease. Nature, 420: 78-84.
61. ZHANG J, MEDAER R, STINISSEN P, HAFLER D, RAUS J. (1993). MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science, 261: 1451-1454.
62. ZIPP F, HARTUNG HP, HILLERT J, SCHIMRIGK S, TREBST C, STANGEL M, INFANTE-DUARTE C, JAKOBS P, WOLF C, SANDBRINK R, POHL C, FILIPPI M. (2006). CCR1 Antagonist Study Group. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology, 67: 1880-1883.